Analysis of Profitability Ratios
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Eli Lilly & Co., profitability ratios
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Eli Lilly & Co. gross profit margin ratio improved from 2022 to 2023 and from 2023 to 2024. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Eli Lilly & Co. operating profit margin ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Eli Lilly & Co. net profit margin ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Eli Lilly & Co. ROE deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Eli Lilly & Co. ROA deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
Gross Profit Margin
Eli Lilly & Co., gross profit margin calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Gross margin | 36,624,400) | 27,041,900) | 21,911,600) | 21,005,600) | 19,056,500) | |
| Revenue | 45,042,700) | 34,124,100) | 28,541,400) | 28,318,400) | 24,539,800) | |
| Profitability Ratio | ||||||
| Gross profit margin1 | 81.31% | 79.25% | 76.77% | 74.18% | 77.66% | |
| Benchmarks | ||||||
| Gross Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | 69.99% | 62.42% | 70.00% | 68.96% | 66.41% | |
| Amgen Inc. | 59.85% | 68.60% | 74.17% | 73.44% | 74.59% | |
| Bristol-Myers Squibb Co. | — | 76.24% | 78.04% | 78.57% | 72.31% | |
| Danaher Corp. | — | 58.74% | 60.21% | 60.95% | 55.98% | |
| Gilead Sciences Inc. | — | 75.87% | 79.03% | 75.56% | 81.23% | |
| Johnson & Johnson | 69.07% | 68.82% | 67.26% | 68.16% | 65.58% | |
| Merck & Co. Inc. | — | 73.17% | 70.63% | 72.02% | 67.74% | |
| Pfizer Inc. | — | 57.34% | 65.77% | 62.08% | 79.26% | |
| Regeneron Pharmaceuticals Inc. | 86.13% | 86.16% | 87.18% | 84.83% | 86.82% | |
| Thermo Fisher Scientific Inc. | — | 39.90% | 42.24% | 50.08% | 49.67% | |
| Vertex Pharmaceuticals Inc. | — | 87.21% | 87.90% | 88.06% | 88.14% | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Gross profit margin = 100 × Gross margin ÷ Revenue
= 100 × 36,624,400 ÷ 45,042,700 = 81.31%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Eli Lilly & Co. gross profit margin ratio improved from 2022 to 2023 and from 2023 to 2024. |
Operating Profit Margin
Eli Lilly & Co., operating profit margin calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Operating income | 12,899,000) | 6,457,900) | 7,127,300) | 6,357,100) | 6,058,000) | |
| Revenue | 45,042,700) | 34,124,100) | 28,541,400) | 28,318,400) | 24,539,800) | |
| Profitability Ratio | ||||||
| Operating profit margin1 | 28.64% | 18.92% | 24.97% | 22.45% | 24.69% | |
| Benchmarks | ||||||
| Operating Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | 16.22% | 23.49% | 31.21% | 31.89% | 24.81% | |
| Amgen Inc. | 22.66% | 29.35% | 38.57% | 31.44% | 37.70% | |
| Bristol-Myers Squibb Co. | — | 16.18% | 17.96% | 15.91% | -21.60% | |
| Danaher Corp. | — | 21.77% | 27.61% | 25.35% | 18.99% | |
| Gilead Sciences Inc. | — | 28.24% | 27.17% | 36.72% | 16.72% | |
| Johnson & Johnson | 23.42% | 24.90% | 24.63% | 24.95% | 23.60% | |
| Merck & Co. Inc. | — | 3.92% | 30.27% | 25.74% | 16.47% | |
| Pfizer Inc. | — | 0.38% | 34.83% | 23.91% | 19.47% | |
| Regeneron Pharmaceuticals Inc. | 28.10% | 30.85% | 38.93% | 55.67% | 42.09% | |
| Thermo Fisher Scientific Inc. | — | 16.00% | 18.69% | 25.57% | 24.19% | |
| Vertex Pharmaceuticals Inc. | — | 38.83% | 48.23% | 36.73% | 46.03% | |
| Operating Profit Margin, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | — | 17.83% | 28.48% | 26.85% | 18.72% | |
| Operating Profit Margin, Industry | ||||||
| Health Care | — | 9.81% | 13.83% | 13.72% | 10.76% | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Operating profit margin = 100 × Operating income ÷ Revenue
= 100 × 12,899,000 ÷ 45,042,700 = 28.64%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Eli Lilly & Co. operating profit margin ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
Net Profit Margin
Eli Lilly & Co., net profit margin calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income | 10,590,000) | 5,240,400) | 6,244,800) | 5,581,700) | 6,193,700) | |
| Revenue | 45,042,700) | 34,124,100) | 28,541,400) | 28,318,400) | 24,539,800) | |
| Profitability Ratio | ||||||
| Net profit margin1 | 23.51% | 15.36% | 21.88% | 19.71% | 25.24% | |
| Benchmarks | ||||||
| Net Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | 7.59% | 8.95% | 20.39% | 20.54% | 10.08% | |
| Amgen Inc. | 12.77% | 24.96% | 26.42% | 24.25% | 29.97% | |
| Bristol-Myers Squibb Co. | — | 17.83% | 13.71% | 15.08% | -21.20% | |
| Danaher Corp. | — | 19.94% | 22.91% | 21.84% | 16.36% | |
| Gilead Sciences Inc. | — | 21.03% | 17.02% | 23.05% | 0.51% | |
| Johnson & Johnson | 15.84% | 41.28% | 18.90% | 22.26% | 17.82% | |
| Merck & Co. Inc. | — | 0.61% | 24.49% | 26.79% | 14.72% | |
| Pfizer Inc. | — | 3.62% | 31.27% | 27.04% | 22.95% | |
| Regeneron Pharmaceuticals Inc. | 31.07% | 30.14% | 35.64% | 50.25% | 41.35% | |
| Thermo Fisher Scientific Inc. | — | 13.99% | 15.47% | 19.70% | 19.79% | |
| Vertex Pharmaceuticals Inc. | — | 36.68% | 37.20% | 30.92% | 43.70% | |
| Net Profit Margin, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | — | 17.99% | 22.59% | 23.42% | 14.10% | |
| Net Profit Margin, Industry | ||||||
| Health Care | — | 8.47% | 10.74% | 11.33% | 8.06% | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Net profit margin = 100 × Net income ÷ Revenue
= 100 × 10,590,000 ÷ 45,042,700 = 23.51%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Eli Lilly & Co. net profit margin ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
Return on Equity (ROE)
Eli Lilly & Co., ROE calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income | 10,590,000) | 5,240,400) | 6,244,800) | 5,581,700) | 6,193,700) | |
| Total Eli Lilly and Company shareholders’ equity | 14,192,100) | 10,771,900) | 10,649,800) | 8,979,200) | 5,641,600) | |
| Profitability Ratio | ||||||
| ROE1 | 74.62% | 48.65% | 58.64% | 62.16% | 109.79% | |
| Benchmarks | ||||||
| ROE, Competitors2 | ||||||
| AbbVie Inc. | 128.66% | 46.94% | 68.60% | 74.91% | 35.30% | |
| Amgen Inc. | 69.59% | 107.78% | 178.97% | 87.96% | 77.20% | |
| Bristol-Myers Squibb Co. | — | 27.27% | 20.37% | 19.46% | -23.84% | |
| Danaher Corp. | — | 8.91% | 14.39% | 14.24% | 9.17% | |
| Gilead Sciences Inc. | — | 24.81% | 21.62% | 29.55% | 0.68% | |
| Johnson & Johnson | 19.68% | 51.11% | 23.36% | 28.20% | 23.25% | |
| Merck & Co. Inc. | — | 0.97% | 31.57% | 34.17% | 27.91% | |
| Pfizer Inc. | — | 2.38% | 32.79% | 28.47% | 15.21% | |
| Regeneron Pharmaceuticals Inc. | 15.03% | 15.22% | 19.14% | 43.03% | 31.86% | |
| Thermo Fisher Scientific Inc. | — | 12.83% | 15.80% | 18.94% | 18.47% | |
| Vertex Pharmaceuticals Inc. | — | 20.59% | 23.88% | 23.19% | 31.22% | |
| ROE, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | — | 20.65% | 27.99% | 29.75% | 17.22% | |
| ROE, Industry | ||||||
| Health Care | — | 18.07% | 22.47% | 22.98% | 16.02% | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
ROE = 100 × Net income ÷ Total Eli Lilly and Company shareholders’ equity
= 100 × 10,590,000 ÷ 14,192,100 = 74.62%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Eli Lilly & Co. ROE deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |
Return on Assets (ROA)
Eli Lilly & Co., ROA calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income | 10,590,000) | 5,240,400) | 6,244,800) | 5,581,700) | 6,193,700) | |
| Total assets | 78,714,900) | 64,006,300) | 49,489,800) | 48,806,000) | 46,633,100) | |
| Profitability Ratio | ||||||
| ROA1 | 13.45% | 8.19% | 12.62% | 11.44% | 13.28% | |
| Benchmarks | ||||||
| ROA, Competitors2 | ||||||
| AbbVie Inc. | 3.17% | 3.61% | 8.53% | 7.88% | 3.07% | |
| Amgen Inc. | 4.45% | 6.91% | 10.06% | 9.63% | 11.54% | |
| Bristol-Myers Squibb Co. | — | 8.43% | 6.53% | 6.40% | -7.61% | |
| Danaher Corp. | — | 5.64% | 8.55% | 7.73% | 4.79% | |
| Gilead Sciences Inc. | — | 9.12% | 7.27% | 9.16% | 0.18% | |
| Johnson & Johnson | 7.81% | 20.98% | 9.57% | 11.47% | 8.41% | |
| Merck & Co. Inc. | — | 0.34% | 13.30% | 12.35% | 7.72% | |
| Pfizer Inc. | — | 0.94% | 15.91% | 12.11% | 6.23% | |
| Regeneron Pharmaceuticals Inc. | 11.69% | 11.95% | 14.85% | 31.75% | 20.47% | |
| Thermo Fisher Scientific Inc. | — | 6.07% | 7.15% | 8.12% | 9.23% | |
| Vertex Pharmaceuticals Inc. | — | 15.92% | 18.30% | 17.44% | 23.07% | |
| ROA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | — | 7.25% | 10.67% | 10.42% | 5.45% | |
| ROA, Industry | ||||||
| Health Care | — | 6.47% | 8.43% | 8.29% | 5.45% | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
ROA = 100 × Net income ÷ Total assets
= 100 × 10,590,000 ÷ 78,714,900 = 13.45%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Eli Lilly & Co. ROA deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level. |